Betahistine, tablets 16 mg 30 pcs

Pharmacological group: Histamine drug

ATX code: N07CA01

Pharmacological properties:

Pharmacodynamics. Agonist of H₁-histamine receptors of the inner ear vessels and antagonist of H₃-histamine receptors of the vestibular nuclei of the CNS. Due to relaxation of precapillary sphincters of the inner ear vessels, it improves blood circulation in the vascular band of the inner ear.

Dose-dependently reduces the generation of action potentials in the neurons of the lateral and medial vestibular nuclei.

Accelerates recovery of vestibular function after unilateral vestibular neurectomy by accelerating and facilitating central vestibular compensation (due to antagonism with H3-histamine receptors).

It relieves symptoms in Meniere’s syndrome and vestibular vertigo. Stable therapeutic effect occurs after 14 days.

Pharmacokinetics. Absorbed rapidly, binding to plasma proteins is less than 5%. Maximum concentration in plasma is after 3 hours. Half-life in 3-4 hours.

Metabolized to inactive metabolites: 2-pyridylacetic acid (the main metabolite) and dimethylbetahistine. 85-90% is excreted by the kidneys as 2-pyridylacetic acid within 24 hours. Excretion of betahistine and dimethylbetahistine by the kidneys is insignificant. The intestine excretes only a small portion of betahistine and its metabolites.

Indications

Active ingredient

Composition

How to take, the dosage

The drug is administered orally, with meals.

Adults and elderly patients:

Tablets 8 mg: 1-2 tablets 3 times daily.

Tablets 16 mg: 1/2-1 tablet 3 times daily.

Tablets 24 mg: 1 tablet 2 times a day .

The improvement is usually noted already at the beginning of therapy, stable therapeutic effect occurs after two weeks of treatment and may build up over several months of treatment. Treatment is prolonged. The duration of therapy is individualized.

There is no data on the need to change therapeutic doses for patients with renal and/or hepatic impairment.

In patients with renal and/or hepatic impairment, there is no data on the need to change therapeutic doses.

Interaction

Special Instructions

Therapeutic effect in some cases builds up within a few months from the start of treatment.
Betahistine has no sedative effect and does not affect the ability to drive or operate machinery.

Contraindications

Hypersensitivity, pregnancy, lactation, childhood.

Lactase deficiency, lactose intolerance, glucose-galactose malabsorption.

Pheochromocytoma.

With caution:

Gastric or duodenal ulcer (history), bronchial asthma. These patients should be monitored regularly during the treatment period.

Pulmonary or duodenal ulcer disease (history).

Side effects

Overdose

Pregnancy use

Similarities